MedTrace Logo

Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma

NCT05031949 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-12-19

No results posted yet for this study

Summary

The purpose of this study is to explore the efficacy and safety of hyperbaric oxygen therapy plus Camrelizumab as a second-line treatment in patients with advanced hepatocellular carcinoma who have failed at least 1 previous treatment.

Conditions

  • Combinational Immunotherapy
  • Hepatocellular Carcinoma Non-Resectable
  • Hyperbaric Oxygen Therapy

Interventions

COMBINATION_PRODUCT

hyperbaric oxygen therapy plus Camrelizumab

Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody

Sponsors & Collaborators

  • Zhang Bi Xiang, MD

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-30
Primary Completion
2024-12-31
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05031949 on ClinicalTrials.gov